脐疗配合耳穴贴压治疗便秘26例

目的 探讨济疗配合耳穴疗法对便秘的疗效。方法 将50例便秘患随机分成两组，治疗组用济部药物贴敷配合耳穴贴压治疗；对照组单纯用于穴贴压治疗，所获数据采用t检验。结果 治疗组有效率96．15％，对照组有效率83．33％，经统计学处理，P＜0．01，有显性差异。结论 济疗联合耳穴贴压治疗便秘疗效较单纯耳穴贴压效果好，且简单方便，无副作用。     

Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users

The introduction of highly active antiretroviral therapy (HAART) has resulted in marked reductions in mortality and acquired immunodeficiency syndrome (AIDS) incidence across all risk groups; however, the proportionate decrease among injecting drug users (IDUs) has been less impressive. Much of the disparity in benefit to IDUs has been a consequence of decreased access to and receipt of potent antiretroviral combinations. Strategies to increase access to and utilization of HAART have included entry into drug treatment and abstinence. Unfortunately, as few as 15%–20% of active drug users in the United States, and in many other countries, are in drug treatment at any one time. We report a pilot project among out-of-drug treatment IDUs infected with human immunodeficiency virus (HIV); HIV therapy was successfully provided to active heroin injectors using the Community Health Care Van (CHCV) at sites of needle exchange. Subjects were willing to initiate, but were not receiving, recommended HIV therapy and were not interested in formal drug treatment. Antiretroviral therapy regimens were selected and linked to heroin injection timing. Weekly visits were scheduled by CHCV staff to assess adverse side effects and encourage adherence. Of the 13 participants, the mean baseline HIV-1 RNA level and CD4 lymphocyte count were 162,369 (log 5.21) copies per milliliter and 265 cells per milliliter, respectively. By 6 months, the proportion whose HIV-1 RNA was below the limits of detection (<400 copies/mL) was 85% (N=11); 77% (N=10) had nondetectable levels by 9 months. By 12 months, 54% (N=7) had a persistently nondetectable viral load, and the net increase in CD4 lymphocyte count was 150 cells per milliliter. As an additional and unintended benefit of this pilot project, 9 (69%) subjects chose to enter drug treatment after achieving a nondetectable viral load. Entry into drug treatment was associated with durability of viral suppression. This small pilot study suggests that health services based on needle exchange may enhance access to HAART among out-of-treatment HIV-infected IDUs. In addition, it demonstrates that this population can benefit from this therapy with the support of a nontraditional, community-based health intervention.     

对CT所见腰椎间盘突出的重新鉴别与治疗观察

目的：因临床发现有些经ＣＴ检查有腰椎间盘突出的患者，其症状体征与ＣＴ结果不符。对１１２ＣＴ阳性者根据症状体征进行重新鉴别。方法：将ＣＴ阳性者根据“三种试验”分为阳性、阴性两组，再选压痛点作注射治疗。结果：两组治疗结果阴性组优良率较高。结论：ＣＴ结果可供参考，但不能作临床考虑的主要依据。对腰椎间盘突出症的诊断与治疗要以症状体征为主     

耳穴压豆法治疗儿童哮喘50例

采用耳穴压豆法治疗儿童哮喘５０例，并随访１年。结果：痊愈１１例；好转３７例；无效２例，总有效率为９６％。认为此法不仅能预防哮喘的发作，还能避免药物引起的副作用。     

Elongation of the cytoplasmic domain,due to a point deletion at exon 7, results in an HLA-C null allele,Cw*0409 N

The development of molecular techniques for HLA typing has allowed the identification of genes previously assigned as serologic blank alleles. Lack or poor cell surface expression has been found for molecules coded by HLA-A, -B, -DRB4, -DRB5, and -DPB1 genes. In this report we describe the first HLA-C gene encoding for a null cell surface molecule. HLA-Cw*0409 N shows a point deletion at position 1095 within exon 7. This mutation provokes a codon reading shift, generating a new translation stop codon 97 bp downstream to that described in alleles normally expressed. This new stop codon location implies the presence of 32 extra amino acid residues in the cytoplasmic domain. Transfection experiments suggest that elongation of the cytoplasmic domain in Cw*0409 N would be the cause of cell surface expression failure, although Cw*0409 N heavy chain is able to create stable complexes with beta2-microglobulin. HLA-C fragment length analysis in a small selected group of samples with B44-Cblk haplotypic associations allowed us to identify two additional subjects showing both a serologic silent Cw*04 allele and a point base deletion at the 3' end of the HLA-C gene. This finding indicates that the allele frequency of Cw*0409 N within serologic C blank alleles would be appreciable, although basically restricted to the (A23)-Cw*0409 N-B*4403-DR7-DQ2 haplotype.     

硒对自身免疫性甲状腺炎大鼠甲状腺超微结构的影响

目的 观察硒干预后自身免疫性甲状腺炎(EAT)大鼠甲状腺超微结构改变,探讨硒对甲状腺自身免疫损伤反应的影响.方法建立自身免疫性甲状腺炎大鼠模型,对患病大鼠预防性和治疗性给予亚硒酸钠,观察其干预后甲状腺病理组织学变化和超微结构改变.结果实验结束时,硒预防EAT组和硒治疗EAT组TgAb、TmAb水平与EAT组相比明显下降(P＜0.05),且光镜下炎性细胞浸润明显减少,滤泡破坏减轻.电镜下EAT组大鼠主要表现为部分滤泡上皮细胞断裂,内质网高度扩张水肿,线粒体明显减少,部分线粒体嵴消失.硒预防组和硒治疗组均可见滤泡形态较规则,内质网扩张程度减轻,线粒体增多且结构趋于正常.结论 硒可预防和减轻自身免疫性甲状腺炎大鼠甲状腺的免疫性损伤.     

EXT1基因1633-26(C→A)突变可能致多发性外生性骨疣

目的研究1例散发多发性外生性骨疣患者的基因突变情况，确定其致病基因。方法采用聚合酶链反应结合DNA直接测序法检测EXT1以及EXT2基因的突变热点区域；并应用错配引物PCR扩增引入酶切位点结合限制性片段长度多态性方法检测和鉴定突变。结果经测序证实在患者EXT1基因的第7内含子3’剪接位点上游26bp处发现一杂合突变，此杂合突变不存在于其表型正常的父母双亲中，是一个新生突变；错配引物扩增与限制性片段长度多态性分析结果表明在150名家系外正常对照者中没有此突变。结论EXT1基因1633-26（C→A）突变可能是导致这个患者发生多发性外生性骨疣的致病突变。     

Ehlers-Danlos syndrome type IV caused by Gly400Glu, Gly595Cys and Glyl003Asp substitutions in collagen III: clinical features, biochemical screening, and molecular confirmation

Three patients with Ehlers-Danlos syndrome type IV (EDS IV) and biochemical evidence of structural defects in collagen III were investigated for mutations within the collagen III gene ( COL3A1 ). Single strand conformation polymorphism analysis of α1(III) cDNA indicated the presence of different heterozygous sequence changes in each of the patients. Nucleotide sequencing revealed mutations leading to the substitution of glycine 400 with glutamic acid, glycine 595 with cysteine, and glycine 1003 with aspartic acid. EDS IV is a life-threatening disorder which, as the clinical histories of our patients and their families show, still often escapes diagnosis. Biochemical and molecular studies can clarify the diagnosis and help provide appropriate management and counselling.     

建设符合自身特点的品牌医院特色文化

本文简述了医院文化自身的特点，着重探讨打造符合自身特点的品牌医院特色文化的措施和途径。     

铁蛋白鉴别胸腹液良恶性质的临界值选择

探讨铁蛋白ferrztin,Ft在鉴别胸腹液良、恶性质的临界值。用RIA法测定218份由不同病因引起的胸腹液标本铁蛋白(pleuraleffusionferritin,PFt)及其同期血清铁蛋白(SFt)。依据临床确诊资料,将标本进行良、恶性病例分组,比较两组PFt、SFt,计算PFt/SFt比值,用ROC曲线选择PFt用于良、恶性质鉴别的最佳临界值。结果表明,良性组PFt为142.4±38.6μg/L,SFt为89.7±43.5μg/L,PFt/SFt为1.46±0.55;恶性组PFt为576.5±239.1μg/L,SFt为189.6±81.7μg/L,PFt/SFt为3.67±1.48;PFt用于鉴别胸腹液良、恶性质的临界值为400μg/L。以恶性积液PFt≥400μg/L、PFt/SFt≥3,良性积液PFt<400μg/L、PFt/SFt<3为实验诊断标准鉴别胸腹腔积液的良、恶性质,灵敏度为84.5%、特异性为87.5%,准确性为92.8%。